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ABSTRACT 
 
UV-curable gels, which polymerise into long-lasting films upon exposure to UVA, have been 
identified as potential topical drug carriers for the treatment of nail diseases. Limitations of 
such films include incomplete drug release and low ungual drug permeation. The aim of the 
work herein was therefore to investigate two strategies, namely: (1) increasing drug release 
from the film, and (2) increasing nailplate permeability, with the ultimate goal of enhancing 
ungual drug permeation. To increase drug release via Strategy 1, a UV-LED lamp (whose 
emitted light was suboptimal for gel polymerisation) was used, and it was hypothesised that 
such a lamp would result in films that are less polymerised/cross-linked and where the drugs 
are less ‘trapped’. Indeed, the suboptimal lamp influenced polymerisation, such that the 
films were thinner, had lower glass transition temperatures and enabled a slightly greater 
(by 15%) drug release of one of the two drugs tested. However, the greater drug release had 
only a modest impact on ungual drug permeation. To evaluate Strategy 2, i.e. increase 
nailplate permeability, chemical ungual enhancers, 2-mercaptoethanol (ME), 2-methyl 
pyrrolidone (NMP), PEG 200 and water were incorporated within the UV-cured films. These 
chemicals caused increased ungual drug permeation, with ME showing the greatest (by 
140%), and water showing the least (by 20%) increase in the amount of drug permeated by 
day 30. Surprisingly, these chemicals also caused increased drug release from the films, 
with ME once again having the greatest effect (by 51%) and water the least effect (by 12%). 
It seems that these chemicals were increasing ungual drug permeation via their influence on 
drug release (i.e. via their impact on the film) as well as via their influence on the nail itself. 
We conclude that, of the two strategies tested, the second strategy proved to be more 
successful at enhancing ungual drug permeation. 
 
Keywords: nail, ungual, drug release, drug permeation, UV-curable gels, topical, UV LED 
lamp 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
While the healthy nail unit is usually considered a cosmetic organ, especially by women, and 
manicuring has a long history (Shapiro, 2014), disorders of the nail unit are common, and 
can affect some or all the parts of the nail apparatus (Rich and Scher, 2003). For example, 
only the paronychial tissues may be affected, or the nail plate’s shape, colour, surface, 
mechanical properties and attachment to the underlying soft tissues may be altered 
(Murdan, 2012). Onychomycosis (fungal infections of the nail) and nail psoriasis are the two 
most common nail disorders and share other similarities, for example, they are of long 
duration, are difficult-to-treat conditions, and have a significant impact on the quality of life 
of sufferers (Arrese and Pierard, 2003; Milobratovic et al., 2013; Ortonne et al., 2010). For 
many sufferers, treatment is important, and topical therapy would be ideal for its avoidance 
of systemic adverse effects and of drug interactions. However, currently available topical 
medicines for onychomycosis and nail psoriasis have low efficacies (Murdan, 2016; Thomas 
et al., 2010). Consequently, much research is being conducted on the formulation of more 
effective topical therapeutics, e.g (Delgado-Charro, 2015; Elsayed, 2015; Kushwaha et al., 
2015) and a range of formulations such as lacquers, films, solutions, hydrogels, patches, 
microemulsions and liposomes have been investigated (Saner et al., 2014; Shivakumar et al., 
2012). 
Recently, a formulation, UV-curable gels, was borrowed from the nail cosmetic industry, and 
investigated for pharmaceutical application (Kerai et al., 2016; Kerai et al., 2015). UVcurable 
gels composed of diurethane dimethacrylate (DUDMA), a reactive (meth)acrylate 
monomer such as ethyl methacrylate or 2-hydroxyethyl methacrylate) or iso-bornyl 
methacrylate, the polymerisation photoinitiator 2-hydroxy-2-methylpropiophenone, 
ethanol and an anti-onychomycotic drug (amorolfine HCl or terbinafine HCl) were 
formulated. Upon gel exposure to a UVA lamp, the photoinitiator absorbs UVA and is 
cleaved into free radicals, which initiate polymerisation reactions among DUDMA and the 
methacrylate monomers, which leads to gel curing into a film. These aesthetically- and 
pharmaceutically- acceptable, visually smooth and transparent films had a long residence in 
vivo in humans, were stable over months at ambient conditions, and enabled drug 
permeation into and through the nail at sufficient levels to show in vitro anti-fungal activity. 
However, drug release from the films was incomplete over the 30-day experiment, being a 
maximum of 50% for amorolfine HCl and 30% for terbinafine HCl. Ungual drug permeation 
into and through the nail plate was low for both drugs, being less than 7% (of the applied 
dose) for amorolfine HCl and less than 5% for terbinafine HCl. 
Such incomplete drug release from the films and low ungual drug permeation are potential 
limitations of the UV-curable formulations. Drug release may become a rate-limiting step if 
insufficient drug is available for ungual permeation. In turn, low levels of drug permeating 
into the nail plate could limit fungal kill and formulation efficacy. The aim of the work 
described in this manuscript was therefore to investigate two strategies for enhancing 
ungual drug permeation, namely: i) increasing drug release from the films and ii) increasing 
nailplate permeability to topically-applied drugs. 
It was hypothesised that drug release from the film could be increased by influencing the gel 
polymerisation process, specifically by allowing polymerisation to occur to an incomplete 
extent, such that the formed film would be less cross-linked and the drug would be less 
‘trapped’ within it. To test the hypothesis, two UVA lamps were used, a traditional UVA 
lamp (which emits UVA in the range of 320–400 nm) and a UV-LED lamp (which emits light 
at 350-375 nm). The LED lamp was expected to cause incomplete polymerisation due to its 
light being suboptimal for the selected photoinitiator, 2-hydroxy-2-methylpropiophenone, 
which has UV absorbance peaks at 245, 280 and 331 nm (Schwalm, 2007). Exposure of the 
photoinitiator to a lower level of UVA from the LED lamp was thus expected to reduce the 
extent of gel polymerisation and the formation of a film where the drug was less ‘trapped’. 
For the second strategy, chemicals which have been shown to act on the nail plate and 
enhance ungual drug permeation were incorporated into the UV-curable gel formulations. It 
was hypothesised that following topical application of the gels, exposure to UVA and 
formation of a film on the nail, the chemical ungual enhancers would be released from the 
film, enter and act on the nail plate to increase the latter’s permeability, which would result 
in increased ungual permeation of the drug. Four ungual enhancers, namely, 2- 
mercaptoethanol (ME), water, 1-methyl-2-pyrrolidinone (NMP) and PEG 200 (properties 
shown in Supplementary material 1), which act via different mechanisms, were selected. 
The thiol, ME, enhances ungual drug permeation by reducing the disulphide bonds of the 
nail keratin, and thereby disrupting the integrity of the nail plate barrier: 
Nail-S-S-Nail + 2[HO-CH2-CH2-SH] ↔ 2Nail-SH + HO-CH2-CH2-S-S-CH2-CH2-OH 
Thiols seem to be the most effective of ungual penetration enhancers investigated so far, 
and ME was found to be the most potent when compared to other thiols, N-acetylcysteine 
and thioglycolic acid (Patel and Vora, 2016). In contrast to the thiol, water, NMP and PEG 
200 do not disrupt the disulfide bonds responsible for the integrity of nail keratin. Instead, 
these chemicals increase nailplate swelling, which can facilitate ungual drug diffusion (Ahn 
et al., 2013; Gunt and Kasting, 2007; Hossin et al., 2016; Nair et al., 2010; Walters and Flynn, 
1983). 
Note that the gel formulations used to evaluate the two strategies were different 
formulations. Strategy 1 was tested using formulations where ethyl methacrylate (EMA) 
was the reactive monomer, while Strategy 2 was tested using formulations where 2- 
hydroxyethyl methacrylate (HEMA) was the reactive monomer. The experiments involved 
with Strategy 1 were conducted first, and by the time Strategy 2 was tested, other work in 
our laboratory had shown that HEMA formulations were superior to EMA formulations, 
enabling a greater drug load, drug release from the films and ungual drug permeation (Kerai 
et al., 2016). Thus, the optimal HEMA formulations were chosen for Strategy 2. 
For both strategies, amorolfine HCl (AH) and terbinafine HCl (TH) were selected as the drugs 
for loading into the films. Terbinafine HCl is the oral anti-onychomycotic drug of choice in 
the UK and much research effort is ongoing to produce a topical anti-onychomycotic 
preparation. Amorolfine HCl is the drug whose topical formulation (Loceryl® nail lacquer) 
has been the most effective topical preparation for many years, prior to the FDA-approval of 
Kerydin® and Jublia® in 2014. A more effective formulation of amorolfine HCl is needed, 
given that the cure rate of Loceryl has been reported to be between 13 and 52% (Murdan, 
2016). Use of both drugs in this study also allows us to determine an effect of drug nature, 
if any, on the two tested strategies. 
 
 
 
 
 
 
 
 
2. Materials and methods 
 
2.1. Materials 
Amorolfine HCl was purchased from Ranbaxy Research Laboratories (Haryana, India) and 
terbinafine HCl from AK Scientific (CA, USA). Diurethane dimethacrylate, EMA, HEMA, 2- 
hydroxy-2-methylpropiophenone, absolute ethanol, methanol, mercaptoethanol, NMP, 
propan-2-ol, triethylamine, phosphoric acid 85% wt. solution in water and trifluoroacetic 
acid were purchased from Sigma–Aldrich (Dorset, UK). Acetonitrile HPLC gradient grade and 
PEG 200 were purchased from Fisher Scientific (Hertfordshire, UK and Loughborough, UK 
respectively). A 36 W Cuccio Professional UVA nail lamp was purchased from Amazon UK 
and a 36 W Professional Salon Quality 18 K UV-LED nail lamp was purchased from eBay UK. 
Nail & Beauty Emporium super absorbent lint-free wipes (4 ply) were purchased from Just 
Beauty UK, an online retailer specialising in professional beauty, hair and skin products. 
Healthy human nail clippings (fingernails) were obtained from male and female volunteers 
aged between 18 and 65 years following ethics approval (REC/B/10/01 School of Pharmacy, 
University of London, UK). 
 
2.2. Preparation of UV gels and films 
 
2.2.1. Preparation of formulations to study the influence of the nature of the UVA lamp 
Gels composed of DUDMA and EMA at a 85:15% v/v ratio, 2-hydroxy-2- 
methylpropiophenone at 3% v/v of the gel mixture, ethanol at 25% v/v of the gel mixture, 
and either 3% w/v AH or 4% w/v TH were used. These formulations were prepared by first 
dissolving the drug in ethanol, and then adding DUDMA, EMA and the photoinitiator and 
stirring the mixture overnight to produce a clear homogenous solution. To prepare the films, 
the gel mixture was applied on a microscope glass slide using a pipette tip (30 μl to an area 
of 15 mm x 15 mm in a single layer), and the glass slide was placed under either a UV-LED 
lamp or a traditional UV lamp for two minutes. This caused gel polymerisation and 
formation of a film. The surface of the film was wiped with propan-2-ol using a nail wipe to 
remove the oxygen inhibition layer (an unreacted monomer layer). This revealed a 
transparent polymer film, which was then removed from the glass slide using a scalpel and 
used in film characterisation experiments as described in Section 2.3. Note, for ungual 
permeation experiments, the gels were cured directly on the dorsal surface of nail clippings 
(rather than on microscope slides). 
 
2.2.2. Preparation of formulations containing ungual penetration enhancers 
Gels composed of DUDMA and HEMA, 2-hydroxy-2-methylpropiophenone, ethanol, and 
either AH (at 4% w/v) or TH (at 6% w/v) were used to investigate the effect of incorporating 
chemical enhancers on ungual drug permeation. Five types of formulations were prepared 
containing either (i) no penetration enhancer (the control), (ii) water, (iii) ME, (iv) NMP or (v) 
PEG 200. The ethanol and penetration enhancer together made up no more than 25% v/v of 
the gel, so that the incorporation of the penetration enhancer would not adversely affect: i) 
gel viscosity (which was typically between 22-23 mPas at 25⁰C), and thereby gel applicability 
on the nail, and ii) the films formed after polymerisation. Details of the gel compositions are 
shown in Table 1. 
The formulations (except where ME was the enhancer) were prepared by mixing ethanol 
and enhancer, dissolving the drug in this mixture, and then adding DUDMA, HEMA and the 
photoinitiator and stirring the mixture overnight to produce a clear homogenous solution. 
The films were prepared as described in Section 2.2.1 using the traditional UVA lamp (which 
emits UVA in the range of 320–400 nm). ME–containing formulations were prepared 
similarly, except that ME was incorporated immediately prior to UV exposure in order to 
prevent premature polymerisation. It was observed that formulations containing ME 
polymerised even in the absence of UVA application. 
The concentration of the penetration enhancer in the gel was the maximum that could be 
incorporated while ensuring that the drug remained in the dissolved state. A maximal 
enhancer concentration was sought, given that ungual drug permeation increases with 
increasing enhancer concentration (Patel and Vora, 2016). In order to determine the highest 
concentrations of enhancer that could be used, gels containing DUDMA, HEMA, the 
photoinitiator, the antifungal drug and penetration enhancers at 2.5, 5, 7.5, 10 or 12.5 % v/v 
with corresponding ethanol concentrations at 22.5, 20, 17.5, 15 or 12.5 % v/v were 
prepared. These formulations were visually observed, exposed to UV light and the resulting 
films were examined by polarised light microscopy and X-ray diffraction. The results showed 
that enhancer concentrations of 10% v/v for water and 5% v/v for ME, NMP and PEG 200 
produced films where the drug remained in the dissolved state while higher concentrations 
resulted in films containing drug crystals. 
 
2.3. In vitro characterisation of the gels and resulting UV-cured films 
 
The in vitro properties of the gels and of the films were determined as described below and 
as previously reported in (Kerai et al., 2016; Kerai et al., 2015). 
 
2.3.1 Gel-to-film mass yield 
The percentage mass conversion from monomer mixture to polymer film was calculated 
using the following equation: 
YIeld (%) = (Wt/W0) x 100 
where W0 is the weight of the monomer mixture before curing and Wt is the weight of the 
UV-cured film. 
 
2.3.2 Fourier Transform Infrared (FT-IR) Spectroscopy to determine degree of 
Polymerisation 
During polymerisation, alkene bonds are converted to alkane ones. The reduction in alkene 
bonds upon curing from monomer mixture to polymer film was therefore taken as an 
indicator of polymerisation, using FTIR. Spectra of the uncured and cured formulations were 
obtained using the OPUS 7.0 software and recorded by a Bruker Alpha IR 
Spectrophotometer (Bruker Corporation, Germany), using 24 scans over the 400 – 4000 cm-1 
range with background subtraction. The % degree of conversion (DC) was calculated from 
the ratio of the height of the absorbance peak of the aliphatic C=C bond (1636 cm-1) relative 
to that of the carbonyl group (>C=O, 1702 cm-1), used as an internal standard, using the 
following equation: 
where (A1636/A1702)0 and (A1636/A1702)t are relative absorbance of C=C bonds to C=O before 
curing and after curing respectively. 
 
2.3.3 The thickness of the films was measured using a Sealey AK9635D 0-25 mm Digital 
External Micrometer (PVR Direct, UK). Each film was measured at three separate points to 
obtain an average and precautions were taken to avoid compressing the film. 
 
2.3.4 Film microstructure was examined by Scanning Electron Microscopy. The samples 
were gold sputter coated (10 nm) and imaged using FEI Quanta 200F (Eindhoven, The 
Netherlands). 
 
2.3.5 The state (crystalline/amorphous) of the drug within the films was determined using 
Polarised Light Microscopy (PLM) and X-Ray Diffraction (XRD). Films were examined by PLM 
for the absence/presence of drug crystals using a Nikon Microphot-FXA microscope (Nikon 
Corporation, Tokyo, Japan) and polarising filters. Images were taken using a Lumenera 
Infinity 2 digital camera (Lumenera Corporation, Ottawa, Canada) attached to the 
microscope. X-ray diffraction spectra of the antifungals and of the polymer films were 
obtained using a Rigaku MiniFlex 600 X-ray diffractometer (Rigaku Corporation, Tokyo, 
Japan) equipped with MiniFlex Guidance software. The samples were scanned over an 
angular range of 2 - 60⁰, with a step size of 0.02⁰ and step duration of 0.5⁰/min. The 
generator voltage was set at 40 kV and the current at 15 mA. The data was analysed using 
OriginPro 9.0. 
 
2.3.6 The levels of residual monomers in the polymer film were quantified by ultrasonic 
extraction. Immediately after curing, one gram of each film was placed in a glass vial and 
three millilitres of methanol was added. The mixture was sonicated for up to 2 hours. 
Subsequently the solvent was analysed using Gas Chromatography to quantify the extracted 
residual monomers. GC was conducted using a 7890A GC System (Agilent, USA) equipped 
with a flame ionisation detector (FID) system. Chromatographic separation was achieved on 
a HP-5 column (30 m long x 320 μm inside diameter with 0.25 μm film thickness). The 
sample injection volume was 2 μl. The injector was in the split mode (100:1) and its 
temperature was maintained at 250 ⁰C throughout the experiments. The column 
temperature was raised from 45 ⁰C (hold 2 min) to 110 ⁰C (hold 2 min) at a 10 ⁰C/min 
heating rate to 280 ⁰C (hold 2 min) at a 20 ⁰C/min heating rate. The flow rate of carrier gas 
(N2) was 1.5ml/min. The detection was carried out by the FID with the temperature of 280 
⁰C and the ratio of H2/air at 25/250. The method developed was validated for linearity, 
precision and accuracy. 
 
2.3.7 The film’s glass transition temperature was determined using Differential Scanning 
Calorimeter (DSC), using the Q2000 TA Instruments (Waters LLC, Delaware, USA), equipped 
with TA Universal Analysis 2000 software. Oxygen-free nitrogen gas with a purge rate of 50 
ml/min was used. Approximately 8 mg of sample was contained within a T-zero pan 
following seal with a T-zero hermetic lid. Each sample was heated from -30 ⁰C to 250 ⁰C with 
a heating rate of 10 ⁰C/min. 
 
2.3.8 The drug-load in UV-cured polymer films was determined by ultrasonic extraction 
using a Transonic T460/H sonicator (Elma, Germany). Ten milligrams of each film was placed 
in a glass vial. Five millilitres of ethanol was added to the film and the vial was sonicated for 
up to 2 hours. Subsequently the solvent was analysed by HPLC (as described in section 
2.3.11). 
 
2.3.9 Drug release from films was measured using Franz diffusion cells, and the drug-loaded 
films were supported on a cellulose membrane. The receptor fluid was a 0.1 M phosphate 
buffer at pH 5 as both amorolfine HCl and terbinafine HCl are stable at this pH (Hossin, 
2015). Sink conditions were maintained throughout the duration of the study. To set up 
the Franz cell, a dialysis tubing cellulose membrane was cut into a circle with an area of 
4.909 cm2. A test formulation was then applied onto the surface of the cellulose membrane, 
covering a circular area of 0.9503 cm2. The cellulose membrane was placed under a UVA 
lamp and the formulation was cured for two minutes. The surface of the film produced was 
then wiped with propan-2-ol using a nail wipe. The cellulose support with the UV-cured film 
was then placed between the donor and receptor compartments of a Franz diffusion cell, 
with the test films facing the donor side, and the compartments were clamped together. 
Subsequently, four ml of receptor fluid was added to the receptor compartment while 
ensuring that no air bubbles were introduced. The diffusion cells were left to stir on a 
magnetic stirrer placed in a water bath maintained at 32 ⁰C. Samples of the receptor fluid 
were collected at pre-determined time intervals for 30 days. Half ml was collected via the 
receptor arm and replaced with 0.5 ml of fresh buffer at each sampling point. The samples 
were analysed by HPLC (as per section 2.3.11) to determine the amount of drug released, 
and the cumulative % drug release over time was plotted. The UV-cured films were also 
observed by polarised microscopy prior to the release study and at day 30 to determine if 
there was any drug crystallisation and precipitation out of the film during the release study. 
 
2.3.10 In vitro ungual drug permeation 
Modified Franz diffusion cells were used. Human fingernail clippings were obtained from 
healthy volunteers aged between 18-65 years, washed with water and soaked in distilled 
water for one hour prior to use. They were then cut to size (circular, with a diameter of 0.3 
cm) and measured for thickness using a micrometre. The formulation (2 μl) was applied on 
the nail surface and cured under a lamp for two minutes. The surface of the film produced 
was then wiped with propan-2-ol using a nail wipe. The nail was placed in the donor 
compartment and fixed into place, such that when assembled with the receptor 
compartment, the under-surface of the nail alone was exposed to the receptor fluid. The 
area exposed was 0.025 cm². Subsequently, 900 μl of receptor fluid was added to the 
receptor compartment. The receptor fluid was 0.1 M phosphate buffer pH 5. The diffusion 
cell was assembled, covered with parafilm, and left to stir on a magnetic stirrer placed in a 
water bath at 32 ⁰C. Samples of the receptor fluid were collected over 30 days by taking 50 
μl of receptor fluid for analysis via the receptor arm and replacing it with 50 μl of fresh 
buffer. The samples were analysed by HPLC (as per section 2.3.11) to determine the amount 
of drug permeated across the nail over time. Each experiment was repeated six times. The 
cumulative amount of antifungal drug permeated through the nail (μg/cm2) (Q) against time 
(t) was plotted and the steady-state flux (J) was calculated from the slope of the linear 
portion of the plot as follows: 
J = ΔQ/Δt 
The apparent permeability coefficient (P) which is defined as the flux divided by the 
concentration of the permeant in the donor compartment (Cd) was calculated using: 
P = J/Cd 
The transport lag time (tL) was estimated by extrapolating the linear portion of the Q versus 
t plot to the x-axis, (i.e. the x-intercept), and the effective diffusion coefficient (Deff) was 
obtained from the transport lag time by the relationship: 
tL= h2/6Deff 
where h represents the thickness of the nail plate, as per (Williams, 2003). 
At the end of the permeation study, the nail clipping was removed from the donor 
compartment using forceps. The film on the nail surface was carefully lifted off the nail 
using a scalpel and placed in a vial containing 1 ml of ethanol. The mixture was 
ultrasonicated for 2 hours and the solvent was analysed by HPLC to quantify the amount of 
drug remaining in the donor compartment. The nail plate was rinsed with distilled water and 
blotted dry with Kimwipes, before placing in a vial containing 1ml of ethanol. This was 
ultrasonicated for 2 hours and the solvent was analysed with HPLC while the nail clipping 
retrieved was placed in another vial containing 1 ml of ethanol for a further two hour 
sonication. This extraction procedure was repeated until no further drug was extracted. The 
total amount of drug extracted from the nail was then calculated. 
 
2.3.11 High-performance liquid chromatography (HPLC) 
 
The amount of amorolfine HCl and terbinafine HCl in samples was quantified by using a 
1260 Infinity Agilent HPLC system equipped with an autosampler and a variable wavelength 
absorbance detector (Agilent Technologies, Germany). Elution was performed using a Luna 
C18 column (150 x 4.6 mm, 5 μm) at a temperature of 40 ⁰C. For amorolfine HCl, the mobile 
phase was 0.1% trifluoroacetic acid: acetonitrile (55:45 v/v), flow rate was 1.0 ml/min, 
sample injection volume was 20.0μl, wavelength was 220 nm and retention time was 5.8 
minutes. For terbinafine HCl, the mobile phase was 0.012M triethylamine + 0.020M 
phosphoric acid: acetonitrile (65:35 v/v), flow rate was 1.0 ml/min, sample injection volume 
was 20.0μl, wavelength was 224 nm and retention time was 8.8 minutes. The method had 
been validated for linearity, precision and accuracy (Hossin, 2015) 
 
2.4 Measurement of temperatures reached in the 2 lamps during operation 
 
The temperatures reached in the UV-LED and traditional UV lamps was measured with an 
Infrared thermometer (RS-1327, range -35⁰C - +500⁰C, RS Components Ltd., UK), to 
determine the temperatures that formulations are exposed to during polymerisation. This 
was to establish whether any differences in the heat generated by the two lamps could 
contribute to differences (if any) in gel polymerisation and properties of the resulting films. 
To monitor the temperature, the lamp was switched on and the temperature at a specific 
point inside the lamp (where the UV-curable gel would usually be placed for polymerisation) 
was measured at times 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 seconds. 
 
2.5. Statistical analysis 
 
All the experiments described above were repeated three times (with the exception of the 
ungual drug permeation which was repeated six times). Statistical calculations were 
conducted using IBM SPSS 22 software. The data was tested for Normality using the 
Shapiro-Wilk test and then analysed using either a t-test (for Normally-distributed data) or 
Mann-Whiney U test (for non-Normally-distributed data) when comparing two groups. For 
multiple group comparisons, ANOVA followed by Tukey (for Normally-distributed data) or 
the Kruskal Wallis test followed by Nemenyi’s test (for non-Normally-distributed data) were 
conducted. Repeated measures ANOVA was conducted to determine whether there were 
differences in the temperature profiles of the two lamps, and in the drug release and ungual 
drug permeation profiles of the formulations. 
 
3. Results 
 
3.1. Influence of the nature of the lamp 
 
3.1.1. Influence of the emitted light on the polymerisation process and on the film formed 
 
The polymerisation pathway has been described previously (Kerai et al., 2015) and is 
schematically shown in Supplementary material 2. Upon gel exposure to a UVA lamp, 
polymerisation is initiated when the photoinitiator absorbs UVA and is cleaved into free 
radicals. The benzoyl radical reacts with an alkene group in DUDMA forming another free 
radical, which reacts with the alkene group in EMA forming another free radical, which 
reacts with an alkene group in another DUDMA molecule, and so forth, such that a 
crosslinked polymer network is ultimately produced. Each DUDMA molecule contains two 
alkene groups, one or both of which can be involved in the polymerisation reactions, and 
thereby be converted into alkane groups.  
Following exposure to a UVA lamp and conversion of a gel formulation into a film, the 
surface of the latter was wiped with an isopropanol-soaked wipe to remove the oxygen 
inhibition layer (an unreacted monomer layer that is formed at the surface of the polymer 
film, where polymerisation is inhibited by atmospheric oxygen (Draelos, 2010; Schoon, 
2005) to reveal a transparent polymer film. Removing the oxygen inhibition layer results in 
a loss of mass, such that the gel to film mass yield is less than 100%, as shown in Table 2 for 
both lamps. A significantly lower gel to mass yield (by about 18%, p<0.05) for the UV-LED 
lamp indicates a greater removal of mass, i.e. a greater amount of unreacted monomer 
layer. This, in turn, led to the UV LED-cured films being thinner (by around 18%, p<0.05). 
Although thinner, the UV-LED cured films were visually similar to those produced by the 
traditional UV lamp. This suggests that the photoinitiator in the gel absorbed sufficient 
photons from the UV-LED lamp to initiate polymerisation reactions. Consequently, the 
extent of polymerisation (indicated by the degree of alkene-to-alkane conversion in the film, 
was similar (p>0.05, Table 2) as were the levels of residual EMA reactants in the films 
(p>0.05). In contrast to EMA, the levels of DUDMA were higher by about 30% in the 
LEDcured films (p<0.05). Despite the statistical significance of the higher DUDMA levels, the 
levels of residual reactants in the films were still very low in all the films, which suggest that 
the less than 100% alkene-to-alkane degrees of conversion during polymerisation (Table 2) 
are due to unreacted alkene groups of DUDMA (which contains two polymerisable C=C 
bonds) within the polymer network, rather than due to unreacted monomers. Indeed the 
values for the alkene to alkane conversion are in line with those reported (i.e. 43-73%) for 
photo-activated methacrylate-based dental composites (Halvorson et al., 2003). 
The films produced by the two lamps were also similar in a range of other parameters. For 
example, both polymer films cured by LED or traditional UV lamps had high uniformity of 
thickness (≥ 95%) and similar smooth and transparent visual appearances, FT-IR spectra 
(Supplementary material 3), X-ray diffractograms and polarised light micrographs 
(Supplementary material 4) which indicated an amorphous nature and absence of drug 
crystals, scanning electron micrographs which showed a dense interior (Fig. 1) and drug 
concentrations which were similar to those in the corresponding gels (Table 2, p>0.05). 
Similar drug concentrations in gels and films showed the drug did not preferentially migrate 
to the film surface or interior during polymerisation with either lamp. In contrast to these 
similarities, the glass transition temperatures of the LED-cured films were lower by about 
10% (Table 2, p<0.05). 
 
3.1.2 Influence of lamp on drug release from the film 
 
Drug release from the films is shown in Figure 2. It can be seen that, for both drugs, a burst 
release occurred during the first 24 hours (due to drug release from the film surface), 
followed by a slower rate of release until a plateau was reached, which was well below 
100% of the total drug load in the film. Examination of the films at the end of the 
experiments showed negligible change in film mass and an absence of drug crystals. Thus, 
drug precipitation in the film during the experiment was ruled out as a possible cause of the 
incomplete drug release. Rather, it seems that the film’s cross-linked nature and dense 
microstructure (Fig. 1) limit the movement of drug molecules through and out of the film. 
Fitting of the release data using zero order, first order and Higuchi models showed the best 
fit to be the Higuchi model (r2≥0.95), which indicates that the drug release following the 
initial burst was diffusion-controlled. 
Figure 2 also shows that terbinafine HCl was released to a much lesser extent compared to 
amorolfine HCl. The lower release of terbinafine HCl from UV-cured films reflects previous 
findings (Kerai et al., 2016; Kerai et al., 2015), and the work herein shows that the lower 
release of terbinafine HCl was maintained when the gel was cured using an LED lamp. It is 
unclear why terbinafine release is about half that of amorolfine; the two drugs have similar 
log P values (5.8 and 5.3 for amorolfine HCl and terbinafine HCl respectively) and molecular 
weights (353.97 and 327.89 Da for amorolfine HCl and terbinafine HCl respectively). A low 
drug release could occur if terbinafine was incorporated in the polymer structure upon 
UVcuring or if terbinafine has a higher affinity to the polymer film compared to amorolfine, 
which would hinder its release. 
When the influence of the lamp on drug release is examined, it can be seen that drug 
release was higher from the films cured by the UV-LED lamp compared to the corresponding 
films cured by the traditional UV lamp; however statistical significance was only achieved for 
amorolfine HCl, from day 15 onwards (Mann Whitney test, p<0.05). 
 
3.1.3 Influence of lamp on ungual drug permeation 
 
The influence of the lamp on ungual permeation is shown in Figure 3, and calculated ungual 
drug permeation parameters are shown in Table 3. From Fig. 3, it can be seen that LEDcured 
films showed slightly greater ungual drug permeation compared to the corresponding 
films cured with the traditional UV lamp over the 30-day experiment, although statistical 
significance was not reached (repeated measures ANOVA, p>0.05). However, the LED lamp 
did cause significantly reduced lag time and increased drug-in-nail levels at the end of the 
experiment for amorolfine HCl (Table 3, also seen in the inset of Fig. 3 as % drug in nail, 
which was 4.3 ± 1.3 vs 1.8 ± 0.9, t test, p<0.05). For terbinafine HCl, the LED lamp increased 
the diffusion coefficient (t test, p<0.05) and the % of drug that permeated through the nail 
(seen in the inset of Fig. 3, which was 1.1 ± 0.3 vs 0.8 ± 0.1, t test, p<0.05). Thus, the LED 
lamp increases ungual drug permeation to some extent, although the influence is small and 
most of the ungual permeation parameters were similar for the UV-LED and the UV-cured 
films (Table 3). Mass balance was 97.0-99.9% (Supplementary material 5). 
When the two drugs are compared, terbinafine HCl showed lower ungual permeation (Fig.3, 
repeated measures ANOVA p<0.05), but similar or higher drug-in-nail levels at the end of 
the experiment (Table 3). This reflects previous reports (Kerai et al., 2016; Kerai et al., 2015) 
and is thought to be due to a greater affinity of terbinafine for the nail keratin (Tatsumi et 
al., 2002) which leads to drug accumulation in the nail plate at the expense of drug exiting 
the nail. 
 
3.2 Influence of the chemical ungual enhancers 
 
3.2.1 Influence of chemical enhancer inclusion on gel polymerisation and film properties 
 
Inclusion of water, ME, NMP and PEG 200 in the gels did not seem to adversely affect 
polymerisation and film formation when the gels were exposed to UVA. The extent of 
polymerisation, measured by the degree of alkene-to-alkane conversion, was between 58- 
67%, the levels of residual monomers were very low (≤1% DUDMA and ≤0.007% HEMA) and 
the values were similar to those for the control formulation (Table 4). Similarly, several 
properties of the films were unchanged by the incorporation of water, ME, NMP or PEG 200. 
For example, there were no changes in film thickness or visual appearance, which remained 
smooth, transparent and aesthetically acceptable. FT-IR and XRD spectra and polarised light 
micrographs showed no obvious differences (Supplementary material 6-7) and scanning 
electron microscopy revealed dense film interiors (Fig. 4) similar to the control films. 
Presence of water, ME, NMP or PEG 200 did not influence drug loads, such that the 
concentrations in the films were similar to those in the uncured gels (p>0.05, Table 4). For 
its part, the nature of drug did not influence the physical appearance of the film or its Tg or 
degree of conversion or levels of residual monomers or yield (p>0.05), reflecting previous 
reports (Kerai et al., 2015). 
There were a few differences however. Films containing mercaptoethanol had significantly 
lower glass transition temperatures as well as increased gel-to-film mass yields (by ~16%, 
p<0.05, compared to the control). Meanwhile the presence of water in the gel formulations 
resulted in films containing ‘bubbles’ (Fig. 5), which could be trapped water or air. 
 
3.2.2 Influence of the penetration enhancers on drug release from the films and on ungual 
drug permeation 
 
Inclusion of a penetration enhancer in the film did not influence the shape of the drug 
release profiles (burst release followed by a slower phase) or the mechanism of drug release 
(diffusion-controlled indicated by the high fit to the Higuchi model), or the impact of drug 
nature (amorolfine HCl being released to a greater extent than terbinafine HCl), but did 
have a significant effect on the extent of drug release (Fig. 6). Irrespective of drug nature, 
drug release was greatest from films containing ME, followed by PEG 200, NMP, water and 
the control, although statistically only the films containing ME, PEG 200 or NMP had greater 
drug release compared to the control (repeated measures ANOVA, p<0.05). At the end of 
the release study, all the films were intact, showed negligible change in mass and no signs of 
drug precipitation. 
The ungual drug permeation profiles and calculated permeation parameters are shown in 
Fig. 7 and Table 5 respectively. From Fig. 7, it can be seen that, for both drugs, the presence 
of mercaptoethanol, NMP and PEG 200 in the films increased ungual drug permeation 
(repeated measures ANOVA, p<0.05 compared to the control) while the presence of water 
had no statistical influence (repeated measures ANOVA p>0.05 compared to the control). 
When all the enhancers were compared, mercaptoethanol was the most effective, 
increasing the flux and permeability coefficient, and reducing the lag time for amorolfine 
HCl, and increasing the diffusion coefficient and reducing the lag time for terbinafine HCl 
(Fig. 7 and Table 5). All the chemicals incorporated in the films, including water, caused a 
significant increase in the level of drug that was measured in the nails at the end of the 30- 
day permeation experiment (Table 5, also seen in inset of Fig. 7). Calculations showed mass 
balance to be 94-97% (shown in Supplementary material 8). 
 
4. Discussion 
 
Influence of the nature of the lamp 
 
We had hypothesised that the use of a UV-LED lamp emitting light at a wavelength that was 
suboptimal for gel curing would result in incomplete polymerisation, and a resulting film 
where the loaded drug would be less ‘trapped’, such that it would be released to a greater 
extent, compared to a traditional ‘optimum’ UV lamp. What we found was that the nature 
of the lamp influenced some, but not all the parameters measured. Reduced gel-to-film 
mass yield and thinner LED cured films resulted when a larger amount of unreacted 
monomer (the oxygen inhibition layer) was removed from the film’s surface following gel 
exposure to LED-UV lamp, which indicates a larger inhibitory influence of atmospheric 
oxygen on polymerisation when the lamp was suboptimal. In addition to the lamp’s 
influence at the surface of the reaction, the film’s interior was also influenced, evidenced by 
lower Tg of LED-cured films and higher levels of residual DUDMA reactants. These indicate a 
less complete gel curing being achieved by the UV-LED lamp, as we had hypothesised. Any 
difference in the amount of heat generated by the UV and UV-LED lamps was ruled out as a 
potential contributor to the differences in polymerisation and film properties, given that the 
temperatures reached within the two lamps were similar (p>0.05, Supplementary material 
9), with temperature increasing by a maximum of 3 oC by the end of the 2-minute gel curing. 
The differences in polymerisation and film are therefore most likely due to the fact that the 
light emitted by the UV-LED lamp (350-375 nm) was not optimal for the photoinitiator, 
whose UV absorbance peaks are at 245, 280 and 331 nm. 
However, despite the UV absorbance peaks of the photoinitiator being outside the range of 
the LED lamp, the light emitted by the UV-LED lamp was still able to cause gel 
polymerisation to a sufficient extent. Consequently, the nature of the lamp did not 
influence the degree of alkene-to-alkane conversion, levels of residual EMA or the film’s 
visual appearance and microstructure, uniformity of thickness, drug concentration, FT-IR 
spectra and amorphous nature. The very low levels of residual EMA and DUDMA monomers 
in the LED-cured films indicate a low risk of allergic contact dermatitis (which can be caused 
by the monomers) and means that, like the traditional UV-cured films, the LED-cured films 
may be used in practice. 
As hypothesised, greater drug release was observed from the incompletely polymerised 
LED-cured films, albeit this was only statistically significant for amorolfine HCl from day 15 
onwards, and was modest (by 13-15% on days 15-30). Such a small effect of the lamp on 
drug release may be explained by the fact that, although suboptimal, the light emitted by 
the LED lamp was sufficient such that many of the film’s properties, which can be expected 
to influence drug release such as the film microstructure, did not change significantly, as 
discussed in the preceding paragraph. The modest enhancement of drug release from 
LEDcured films had, in turn, a modest influence on ungual drug permeation, with increase in 
some of the ungual permeation parameters for the two drugs. This shows that modulation 
of gel polymerisation by the use of a suboptimal lamp is possible, but is not a very effective 
strategy for enhancing ungual drug permeation, and highlights the importance of evaluating 
the second strategy discussed below. 
 
Influence of chemical ungual enhancers 
 
Water, ME, NMP and PEG 200 have boiling points of 100⁰C, 157⁰C, 202⁰C and >250⁰C 
respectively. As such, they are not expected to evaporate off during gel curing, and are 
therefore expected to remain in the film. This could explain the ‘bubbles’ seen in the light 
micrographs of the films containing water (Fig. 5), if the water was not uniformly dispersed 
within the film, but was concentrated into ‘droplets’. Otherwise, incorporation of water, 
ME, NMP and PEG 200 in the gels did not adversely affect polymerisation. On the contrary, 
inclusion of ME seems to enhance polymerisation, resulting in an increased gel-to-film mass 
yield. This reflects the observation made during gel preparation (described in Section 2.2.2) 
that formulations containing mercaptoethanol polymerised even in the absence of UVA 
application. The greater gel-to-film mass yield could be due to a thinner oxygen inhibition 
layer formed, and subsequently removed. As mentioned above, the oxygen inhibition layer 
is formed due to the inhibition of polymerisation by atmospheric oxygen. The latter reacts 
with the initiating or propagating radicals to form peroxyl radicals (Supplementary material 
10) which are unreactive towards the (meth)acrylate C=C bond, and thereby terminate 
polymerisation through radical-radical recombination (Odian, 1991; Rabek, 1993). Thiols are 
known to reduce the inhibitory effects of O2 on resin formulations (Hoyle and Bowman, 
2010). In the presence of initiating radicals, hydrogen transfer by the thiol provides a thiyl 
radical which can propagate the polymerisation reactions. Peroxyl radicals can also abstract 
hydrogen from thiol, and as a result reinitiation occurs by a thiyl radical and polymerisation 
can continue (Supplementary material 10) (Ligon et al., 2014). Participation of ME in the 
polymerisation reactions via thiyl radicals has a considerable influence on the polymer film 
formed, whose Tg was significantly reduced. The thiyl radicals may be interfering with 
polymer cross-linking, causing greater flexibility of the polymer chains and a lower Tg (Table 
4). 
Incorporation of the chemicals had a significant influence on drug release (Fig. 6). We 
speculate that the increase in drug release was caused by the ungual enhancers’ influence 
on the polymer network, which in this case, is indicated by their influence on the degree of 
alkene-to-alkane conversion (Table 4). A lower alkene-to-alkane conversion during gel 
polymerisation indicates lesser cross-linking in the resulting polymer, which in turn would 
allow greater polymer chain flexibility and greater free volume in the polymer, which would 
allow greater drug diffusion and drug release out of the film. Indeed a high correlation was 
found between degree of conversion and drug released by day 30 (Spearma’s rho 
correlation r= -0.9, p<0.05 for both amorolfine HCl and terbinafine HCl). 
The enhanced drug release by the incorporation of chemicals was reflected in enhanced 
ungual drug permeation, with similarities between the rank orders for the permeation and 
release profiles. This indicates that the chemicals were exerting their ungual permeation 
enhancing effect, at least to some extent, via their influence on drug release. ME was the 
most promising enhancer, as expected from the literature. While the other chemicals, NMP, 
PEG 200 or water had a smaller influence on the ungual permeation profiles, these 
chemicals increased drug-in-nail levels measured at the end of the permeation experiment 
to similar extents compared to ME (p>0.05). This dichotomy, i.e. similar increase in drug-
innail levels with lower increases in drug permeation through the nail indicates that NMP, 
PEG 200 and water induced changes in the nailplate which caused the latter to retain the 
drug (rather than allowing the drug to exit out of the nail). These chemical enhacers were 
therefore acting on the nailplate itself (as well as on the film). Greater drug-in-nail levels at 
the expense of drug flux out of the nail, shown by NMP, PEG 200 and water, may be a 
positive effect. High drug-in-nail levels in vivo could mean a drug reservoir in the nail plate, 
which enables a longer-term drug depot to (i) kill the fungus and any newly-germinating 
fungal spores residing in the nail plate, and (ii) permeate into and exert antifungal activity in 
the nail bed. 
 
4. Conclusions 
 
We set out to compare two strategies for enhancing ungual drug permeation from UV-cured 
films. The first strategy – of increasing drug release from films by reducing the extent of 
polymerisation – had modest effects on drug release and on ungual drug permeation. In 
contrast, the second strategy – of increasing ungual drug permeability using chemicals – 
enhanced ungual drug permeation considerably. Interestingly, inclusion of the chemicals 
also increased drug release from the films. This poses the question of whether drug 
permeation was enhanced via a chemical’s action on the nail plate permeability or via the 
chemical’s action on drug release from the film. Similarities in the rank orders of drug 
release and ungual permeation profiles suggest that, to a certain extent, the chemical 
enhancers enhanced ungual permeation via their influence on the film i.e. by enhancing 
drug release. However, a considerable role of the chemical enhancer’s action on the 
nailplate itself, which led to greatly increased drug-in-nail levels, was also found. We 
conclude that the chemicals enhanced ungual permeation from UV-cured films, via both 
their influences on the film (drug vehicle) and on the nail plate. 
 
Acknowledgements 
 
The authors thank UCL School of Pharmacy for funding this work and are grateful to the 
volunteers who donated their nail clippings used in the in vitro permeation studies. 
 
References 
Ahn, T., Lee, J.-P., Kim, J., Oh, S., Chun, M.-K., Choi, H.-K., 2013. Effect of Pressure Sensitive Adhesive 
and Vehicles on Permeation of Terbinafine Across Porcine Hoof Membrane. Archives of 
Pharmaceutical Research 36, 1403-1409. 
Arrese, J.E., Pierard, G.E., 2003. Treatment failures and relapses in onychomycosis: A stubborn 
clinical problem. Dermatology 207, 255-260. 
Delgado-Charro, M.B., 2015. A pharmaceutics perspective on drug delivery to the nail: recent 
advances and challenges. Therapeutic delivery 6, 773-775. 
Draelos, Z.D., 2010. Cosmetic Dermatology: Products and Procedures. Wiley-Blackwell, Oxford. 
Elsayed, M.M.A., 2015. Development of topical therapeutics for management of onychomycosis and 
other nail disorders: A pharmaceutical perspective. J. Controlled Release 199, 132-144. 
Gunt, H.B., Kasting, G.B., 2007. Effect of Hydration on the Permeation of Ketoconazole Through 
Human Nail Plate In Vitro. European Journal of Pharmaceutical Sciences 32, 254-260. 
Halvorson, R.H., Erickson, R.L., Davidson, C.L., 2003. The Effect of Filler and Silane Content on 
Conversion of Resin-Based Composite. Dental Materials 19, 327-333. 
Hossin, B., 2015. The Rational Design of an Antifungal Nail Lacquer Using the Hansen Solubility 
Parameter Concept, UCL School of Pharmacy. University College London, London. 
Hossin, B., Rizi, K., Murdan, S., 2016. Application of Hansen Solubility Parameters to Predict Drug- 
Nail Interactions, which can Assist the Design of Nail Medicines. European Journal of Pharmaceutics 
and Biopharmaceutics 102, 32-40. 
Hoyle, C.E., Bowman, C.N., 2010. Thiol-ene Click Chemistry. Angewandte Chemie International 
Edition in English 49, 1540-1573. 
Kerai, L.V., Hilton, S., Maugueret, M., Kazi, B.B., Faull, J., Bhakta, S., Murdan, S., 2016. UV-curable 
gels as topical nail medicines:In vivo residence, anti-fungal efficacy and influence of gel components 
on their properties. Int. J. Pharm. 514, 244-254. 
Kerai, L.V., Hilton, S., Murdan, S., 2015. UV-curable gel formulations: Potential drug carriers for the 
topical treatment of nail diseases. Int. J. Pharm. 492, 177-190. 
Kushwaha, A., Murthy, R.N., Murthy, S.N., Elkeeb, R., Hui, X., Maibach, H.I., 2015. Emerging therapies 
for the treatment of ungual onychomycosis. Drug Dev. Ind. Pharm. 41, 1575-1581. 
Ligon, S.C., Husár, B., Wutzel, H., Holman, R., Liska, R., 2014. Strategies to Reduce Oxygen Inhibition 
in Photoinduced Polymerization. Chemical Reviews 114, 557-589. 
Milobratovic, D., Jankovic, S., Vukicevic, J., Marinkovic, J., Jankovic, J., Railic, Z., 2013. Quality of life 
in patients with toenail onychomycosis. Mycoses 56, 543-551. 
Murdan, S., 2012. The Nail: Anatomy, Physiology, Diseases, and Treatment, in: Murthy, S.N., 
Maibach, H. (Eds.), Topical Nail Products and Ungual Drug Delivery. CRC Press, Boca Raton, pp. 1-36. 
Murdan, S., 2016. Nail disorders in older people, and aspects of their pharmaceutical treatment. Int. 
J. Pharm., in press. 
Nair, A.B., Chakraborty, B., Murthy, S.N., 2010. Effect of Polyethylene Glycols on the Trans-ungual 
Delivery of Terbinafine. Current Drug Delivery 7, 407-414. 
Odian, G., 1991. Principles of Polymerisation. Wiley & Sons, New York. 
Ortonne, J.P., Baran, R., Corvest, M., Schmitt, C., Voisard, J.J., Taieb, C., 2010. Development and 
validation of nail psoriasis quality of life scale (NPQ10). J. Eur. Acad. Dermatol. Venereol. 24, 22-27. 
Patel, M., Vora, Z., 2016. Formulation Development and Optimization of Transungual Drug Delivery 
System of Terbinafine Hydrochloride for the Treatment of Onychomycosis. Drug Delivery and 
Translational Research 6, 263-275. 
Rabek, J.F., 1993. Experimental and Analytical Methods for the Investigation of Radiation Curing, in: 
Fouassier, J.P., Rabek, J.F. (Eds.), Radiation Curing in Polymer Science and Technology. Elsevier, 
London, p. 329. 
Rich, P., Scher, R.K., 2003. An Atlas of Diseases of the Nail. The Parthenon Publishing Group, London. 
Saner, M.V., Kulkarni, A.D., Pardeshi, C.V., 2014. Insights into drug delivery across the nail plate 
barrier. J. Drug Target. 22, 769-789. 
Schoon, D.D., 2005. Nail Structure and Product Chemistry, 2nd Edition ed. Milady, a Part of Cengage 
Learning, USA. 
Schwalm, R., 2007. Raw Materials, in: Schwalm, R. (Ed.), UV Coatings: Basics, Recent Developments 
and New Applications, First ed. Elsevier, Oxford, pp. 95-140. 
Shapiro, S.E., 2014. Nails, The Story of the Modern Manicure. Prestel, Munich. 
Shivakumar, H.N., Juluri, A., Desai, B.G., Murthy, S.N., 2012. Ungual and Transungual drug delivery. 
Drug Dev. Ind. Pharm. 38, 901-911. 
Tatsumi, Y., Yokoo, M., Senda, H., Kakehi, K., 2002. Therapeutic Efficacy of Topically Applied KP-103 
against Experimental Tinea Unguium in Guinea Pigs in Comparison with Amorolfine and Terbinafine. 
Antimicrobial Agents and Chemotherapy 46, 3797-3801. 
Thomas, J., Jacobson, G.A., Narkowicz, C.K., Peterson, G.M., Burnet, H., Sharpe, C., 2010. Toenail 
onychomycosis: an important global disease burden. J. Clin. Pharm. Ther. 35, 497-519. 
Walters, K.A., Flynn, G.L., 1983. PERMEABILITY CHARACTERISTICS OF THE HUMAN NAIL PLATE. 
International Journal of Cosmetic Science 5, 231-246. 
Williams, A.C., 2003. Transdermal and Topical Drug Delivery. Pharmaceutical Press, London. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
